Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient

Ji Yuan, Radhika Shah, Anita Kulharya, Celalettin Ustun

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aneuploidy is a very common prognostic factor in multiple myeloma (MM). Nonhyperdiploidy including near-tetraploidy (NT) is a poor prognostic indicator, compared to hyperdiploidy in multiple myeloma (MM). NT results from endoduplication of hypodiploidy. We report of a 55-year-old female patient diagnosed with advanced stage MM with hyperdiploidy and t(8;14)(q24;q32). The patient responded well to lenalidomide and dexamethasone for approximately 1 year. At the time of progression, she had become unresponsive to lenalidomide and subsequently bortezomib, and was found to have NT and loss of choromosome13. There is another reported patient who had a possible interchange from nonhyperdiploidy to hyperdiploidy status, however, artifact could not be ruled out. To our knowledge, this is the first patient in whom evolution of an abnormal clone from a hyperdiploidy to a NT abnormal clone has been confirmed during the natural course of MM. This evolution is associated with resistance to novel drugs and poor prognosis in MM.

Original languageEnglish (US)
Pages (from-to)954-957
Number of pages4
JournalLeukemia Research
Volume34
Issue number7
DOIs
StatePublished - Jul 1 2010

Fingerprint

Polyploidy
Tetraploidy
Multiple Myeloma
Clone Cells
Aneuploidy
Artifacts
Dexamethasone
Bortezomib
lenalidomide
Pharmaceutical Preparations

Keywords

  • Bortezomib
  • C-Myc
  • Del13
  • Hyperdiploid
  • Lenalidomide
  • Multiple myeloma
  • Near-tetraploid
  • Nonhyperdiploid
  • T(8 ;14)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient. / Yuan, Ji; Shah, Radhika; Kulharya, Anita; Ustun, Celalettin.

In: Leukemia Research, Vol. 34, No. 7, 01.07.2010, p. 954-957.

Research output: Contribution to journalArticle

@article{c254b7a705a74414bc86a8ce9a2f48d0,
title = "Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient",
abstract = "Aneuploidy is a very common prognostic factor in multiple myeloma (MM). Nonhyperdiploidy including near-tetraploidy (NT) is a poor prognostic indicator, compared to hyperdiploidy in multiple myeloma (MM). NT results from endoduplication of hypodiploidy. We report of a 55-year-old female patient diagnosed with advanced stage MM with hyperdiploidy and t(8;14)(q24;q32). The patient responded well to lenalidomide and dexamethasone for approximately 1 year. At the time of progression, she had become unresponsive to lenalidomide and subsequently bortezomib, and was found to have NT and loss of choromosome13. There is another reported patient who had a possible interchange from nonhyperdiploidy to hyperdiploidy status, however, artifact could not be ruled out. To our knowledge, this is the first patient in whom evolution of an abnormal clone from a hyperdiploidy to a NT abnormal clone has been confirmed during the natural course of MM. This evolution is associated with resistance to novel drugs and poor prognosis in MM.",
keywords = "Bortezomib, C-Myc, Del13, Hyperdiploid, Lenalidomide, Multiple myeloma, Near-tetraploid, Nonhyperdiploid, T(8 ;14)",
author = "Ji Yuan and Radhika Shah and Anita Kulharya and Celalettin Ustun",
year = "2010",
month = "7",
day = "1",
doi = "10.1016/j.leukres.2010.01.013",
language = "English (US)",
volume = "34",
pages = "954--957",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient

AU - Yuan, Ji

AU - Shah, Radhika

AU - Kulharya, Anita

AU - Ustun, Celalettin

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Aneuploidy is a very common prognostic factor in multiple myeloma (MM). Nonhyperdiploidy including near-tetraploidy (NT) is a poor prognostic indicator, compared to hyperdiploidy in multiple myeloma (MM). NT results from endoduplication of hypodiploidy. We report of a 55-year-old female patient diagnosed with advanced stage MM with hyperdiploidy and t(8;14)(q24;q32). The patient responded well to lenalidomide and dexamethasone for approximately 1 year. At the time of progression, she had become unresponsive to lenalidomide and subsequently bortezomib, and was found to have NT and loss of choromosome13. There is another reported patient who had a possible interchange from nonhyperdiploidy to hyperdiploidy status, however, artifact could not be ruled out. To our knowledge, this is the first patient in whom evolution of an abnormal clone from a hyperdiploidy to a NT abnormal clone has been confirmed during the natural course of MM. This evolution is associated with resistance to novel drugs and poor prognosis in MM.

AB - Aneuploidy is a very common prognostic factor in multiple myeloma (MM). Nonhyperdiploidy including near-tetraploidy (NT) is a poor prognostic indicator, compared to hyperdiploidy in multiple myeloma (MM). NT results from endoduplication of hypodiploidy. We report of a 55-year-old female patient diagnosed with advanced stage MM with hyperdiploidy and t(8;14)(q24;q32). The patient responded well to lenalidomide and dexamethasone for approximately 1 year. At the time of progression, she had become unresponsive to lenalidomide and subsequently bortezomib, and was found to have NT and loss of choromosome13. There is another reported patient who had a possible interchange from nonhyperdiploidy to hyperdiploidy status, however, artifact could not be ruled out. To our knowledge, this is the first patient in whom evolution of an abnormal clone from a hyperdiploidy to a NT abnormal clone has been confirmed during the natural course of MM. This evolution is associated with resistance to novel drugs and poor prognosis in MM.

KW - Bortezomib

KW - C-Myc

KW - Del13

KW - Hyperdiploid

KW - Lenalidomide

KW - Multiple myeloma

KW - Near-tetraploid

KW - Nonhyperdiploid

KW - T(8 ;14)

UR - http://www.scopus.com/inward/record.url?scp=77952959375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952959375&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2010.01.013

DO - 10.1016/j.leukres.2010.01.013

M3 - Article

C2 - 20138360

AN - SCOPUS:77952959375

VL - 34

SP - 954

EP - 957

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 7

ER -